摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

二甲氧基四氢呋喃 | 73510-05-1

中文名称
二甲氧基四氢呋喃
中文别名
——
英文名称
dimethoxytetrahydrofuran
英文别名
2,2-dimethoxytetrahydrofuran;dimethoxydihydrofuran;2,2-Dimethoxy-tetrahydro-furan;Dimethoxytetrahydrofurane;2,2-dimethoxyoxolane
二甲氧基四氢呋喃化学式
CAS
73510-05-1
化学式
C6H12O3
mdl
——
分子量
132.159
InChiKey
HRRAHRNQUBBIAR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    65 °C(Press: 10 Torr)
  • 密度:
    1.02±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    27.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME
    申请人:Popov Andrei
    公开号:US20130096083A1
    公开(公告)日:2013-04-18
    The use of isoquinolones for preparing drugs, including novel isoquinolones as well as their synthesis method. In particular, isoquinolone derivatives used in the treatment of pathological angiogenesis, and more particularly of cancer.
    使用异喹啉类化合物制备药物,包括新型异喹啉类化合物及其合成方法。特别是用于治疗病理性血管生成的异喹啉类衍生物,尤其是用于治疗癌症。
  • [EN] INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF<br/>[FR] INHIBITEURS DE RÉPLICATION DU VIRUS DE LA GRIPPE ET UTILISATIONS ASSOCIÉES
    申请人:SUNSHINE LAKE PHARMA CO LTD
    公开号:WO2018108125A1
    公开(公告)日:2018-06-21
    The invention provides a class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    本发明提供了一类作为流感病毒复制抑制剂的化合物、其制备方法、含有这些化合物的药物组合物,以及这些化合物和药物组合物在治疗流感中的用途。
  • Anti-HCV nucleoside derivatives
    申请人:——
    公开号:US20030008841A1
    公开(公告)日:2003-01-09
    The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.
    本发明涉及新颖和已知的嘌呤和嘧啶核苷衍生物,已发现这些衍生物对丙型肝炎病毒(HCV)具有活性。本发明声明利用这些衍生物治疗HCV感染,以及本文所披露的新颖核苷衍生物。
  • [EN] PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS<br/>[FR] ACIDES PHÉNYLSULFAMOYLBENZOÏQUES EN TANT QUE MODULATEURS D'ERAP1
    申请人:GREY WOLF THERAPEUTICS LTD
    公开号:WO2020225569A1
    公开(公告)日:2020-11-12
    The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally substituted by one ormore substituents selected from alkyl, cycloalkyl, halo, alkoxy, CN, haloalkyl and OH; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, C land alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl,Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl andhaloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl,SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionallysubstituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl and halo; and R9 is H, alkyl or halo; R10 and R11 are each independently H or alkyl; and R12 and R13 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immuno- oncology and related applications. Another aspect of the invention relates to compounds of formulae (la) and (lb).
    本发明涉及一种具有式(I)的化合物,或其药学上可接受的盐或水合物,其中:基团X-Y为-NHSO2-或-SO2NH-;Z为单环芳基或杂环芳基,每个基团可选择地由一种或多种从烷基、环烷基、卤素、烷氧基、CN、卤代烷基和羟基中选择的取代基取代;R1为H或烷基;R2从COOH和四唑基团中选择;R3从H、C和烷基中选择;R4从H和卤素中选择;R5从H、烷基、卤代烷基、SO2-烷基、Cl、烷氧基、OH、CN、羟基烷基、烷基硫、杂环芳基、环烷基、杂环烷基和卤代烷氧基中选择;R6为H;R7从H、CN、卤代烷基、卤素、SO2-烷基、SO2NR12R13、杂环芳基、CONR10R11和烷基中选择,其中所述的杂环芳基可选择地由一种或多种从烷基、卤素、烷氧基、CN、卤代烷基和羟基中选择的取代基取代;R8从H、烷基、卤代烷基和卤素中选择;R9为H、烷基或卤素;R10和R11各自独立地为H或烷基;R12和R13各自独立地为H或烷基。本发明的进一步方面涉及这些化合物在免疫肿瘤学领域及相关应用中的用途。本发明的另一个方面涉及式(la)和(lb)的化合物。
  • Total Synthesis of Resiniferatoxin Enabled by Radical-Mediated Three-Component Coupling and 7-<i>endo</i> Cyclization
    作者:Satoshi Hashimoto、Shun-ichiro Katoh、Takehiro Kato、Daisuke Urabe、Masayuki Inoue
    DOI:10.1021/jacs.7b10177
    日期:2017.11.15
    as the radical precursor and the allylic dithiocarbonate as the terminator. The second radical reaction thus enabled not only the 7-endo cyclization but also construction of the C8-stereocenter and the C6-exo olefin. Tricycle 14 was elaborated into the targeted 1 by a series of highly optimized chemoselective reactions. The present total synthesis of 1 demonstrates the advantages of radical reactions
    Resiniferatoxin (1) 属于 daphnane diterpenoid 家族,对 TRPV1 具有强烈的激动作用,TRPV1 是一种有害温度和化学刺激的传感器。1 的高密度氧化反式融合 5/7/6-三碳环(ABC 环)对化学合成提出了艰巨的挑战。在这里,我们报告了一种新的基于自由基的策略的开发,用于从三个组件组装 1:A 环 9、烯丙基锡烷 18b 和 C 环 17b。由 d-核糖衍生物 19 制备的 6 元 17b 被设计为具有笼状原酸酯结构,α-烷氧基硒化物作为自由基前体。用 18b、9 和 V-40 处理 17b 后,从 17b 生成了具有强反应性的 α-烷氧基桥头自由基,然后依次与 9 和 18b 偶联得到 16b。第一个自由基反应形成了受阻的 C9,A 环和 C 环之间的 10-连接并以立体选择性方式扩展 A 环上的 C4 链。在将 16b 衍生为 15 后,剩余的
查看更多